ORCHIDPHAR

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange regarding a press release being issued on June 29,2005 by the company in respect of approval received by the company from the USFDA for its ANDA(Abbreviated New Drug Application) of Cephalexin capsules USP 250 mg and 500 mg. The company has further informed that this is the first ANDA approval received by the company in the oral formulations segments in the US . The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Com

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange regarding the following, which has been considered at a meeting of the Board of Directors of Orchid Chemicals & Pharmaceuticals Limited, held on June 15, 2005:- a)Raising of Additional long term resources:- In order to meet the further financial outlay on Multi-therapeutic expansion and to reduce the interest burden, the Company proposes to raise long terms funds by way of issue of GDRs in the International Market of US$ 100 million, with additional 15% Green Shoe Option. b)Issue of Warrants:- Issue of 25 lakh Warrants, convertib

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that Shri Anil Thadani has been appointed as Director, to fill up the casual vacancy caused by the resignation of Shri Sanjay K Sehgal. The change is effective from June 15, 2005.

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that a press release dated June 06, 2005, is being issued by the Company in respect of the Company's Research & Development (R&D) centre located in Chennai, which has received the Good Laboratory Practices (GLP) certification. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that Industrial Development Bank of India has withdrawn the nomination of Shri M.K.Chouhan and instead appointed Shri S Andi,General Manager ,Corporate Finance Dept.(I),Industrial Development Bank of India Limited,Mumbai as its nominee on the board of the Company w.e.f May 19,2005.

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that Orchid has signed a fresh marketing pact with Par Pharma for 4 non-antibiotic products for distribution in the US generics market. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that the Board of Directors of the Company, at it's meeting held on April 27, 2005 have allotted 11,800 equity shares of Rs.10/- each (8250 shares at 243.35 per share and 3550 at Rs.252/- per share) to the employees under ESOP 1999 Scheme. The equity shares allotted will be locked in a for a period of one year from the date of Allotment. Further the company has informed that the Compensation Committee of the Board on April 27,2005 approved the issue of 2,92,075 stock options to employees. The stock options are convertible into e

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that the company has issued a press release dated April 27, 2005 titled 'Orchid registers turnover of Rs 689 crore during 2004-05 - Net profit at Rs 31 crore'. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that the BODs of the Company at its meeting held on April 27, 2005 have recommended a dividend of 40% (Rs. 4 per share) on the equity share of Rs. 10 each.

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that Orchid has received the formal approval from the USFDA for its Abbreviated New Drug Application (ANDA) for its formulation product Cefazolin for Injection USP, in 500 mg/vial and 1 gm/vial strengths. The Company has further informed that this is the first ANDA approval for the Company. The approval of USFDA for the ANDA enables the Company to launch the product in the US.

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that a press release dated March 16, 2005, is being issued by the Company in respect of an exclusive agreement entered with M/s. STADA Pharmaceuticals, Inc. (STADA), the U.S. subsidiary of STADA Arzneimittel AG, for the development and supply of six prescription generic drug products to STADA for the US market. Through this agreement, Orchid will develop and exclusively manufacture these non-cephalosporin formulations for exclusive distribution and marketing by STADA in the US market. The details of the press release shall be av

K Raghavendra Rao has informed the Exchange that Orchid Chemicals & Pharmaceuticals Ltd on March 01,2005 have allotted:1) 7,50,000 equity shares of Rs.10 each arising out of the conversion of 7,50,000(out of total allotted warrants of 9,50,000) warrants issued on private placement basis to Mrs. R Vijayalakshmi.2) 10,00,000 equity shares of Rs.10 each arising out of the conversion of total allotted 10,00,000 warrants issued on private placement basis to M/s Orchid Health Care Private Limited. Subsequent to the above allotment, the aggregate shareholding of K Raghavendra Rao along with persons

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that persons acting in concert R.Vijaya Lakshmi, K Raghavendra Rao and Orchid Health Care Private Limited have acquired 1,750,000 shares aggregating to 4.36% of the total share capital of Orchid Chemicals and Pharmaceuticals Limited on March 01,2005.The mode of acquisition is conversion of warrants into equity shares. The shareholding of R.Vijaya Lakshmi, K Raghavendra Rao and Orchid Health Care Private Limited after the said acquisition is 6,620,310 shares aggregating to 19.40% of the total share capital of the company.

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that the Company has issued a press release dated March 07, 2005, in respect of the Company's generic formulations facility located at Irungattukottai inspected by USFDA. The inspection covered the full spectrum of oral and sterile formulation manufacturing blocks and nine Abbreviated New drug Applications (ANDAs) each spanning 4 dosage forms of sterile injectables, tablets, capsules and dry powder syrups. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest A

Orchid Health Care Private Limited has informed the Exchange that Orchid Chemicals & Pharmaceuticals Ltd on March 01,2005 have allotted 10,00,000 equity shares of Rs.10 each arising out of the conversion of total allotted 10,00,000 warrants issued on private placement basis. Subsequent to this allotment, the holding of Orchid Health Care Private Limited has increased to 16,24,610 shares(4.76% of the total share capital).

R.Vijayalakshmi has informed the Exchange that Orchid Chemicals & Pharmaceuticals Ltd on March 01,2005 have allotted 7,50,000 equity shares of Rs.10 each arising out of the conversion of 7,50,000 (out of total allotted warrants of 9,50,000) warrants issued on private placement basis. Subsequent to this allotment, the holding of R.Vijayalakshmi has increased to 8,08,918 shares(2.37% of the total share capital).

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that the Allotment committee of the BOD's of the company on March 01, 2005, have allotted 17,50,000 equity shares of Rs.10/- each arising out of the conversion of 17,50,000 (out of the total allotted warrants of 20,00,000) warrants issued on private placement basis to the following person(s) / Company : 1) Promoter/Promoter Group:- Mrs R Vijayalakshmi (W/o Shri K Raghavendra Rao, Managing Director & Promoter of the Company) - 750,000 equity shares; 2) M/s Orchid Health Care Private Limited (A Company jointly owned by Shri K Ragha

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that the Company has issued a press release dated February 24, 2005, in respect of the Company's exclusive pact with Alpharma Inc. to market oral non-antibiotic formulations in the US and European markets. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that the company has issued a press release dated January 20, 2005 titled 'Orchid registers turnover of Rs.172 crore during Q3 FY 2004-05 '. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Clarification of News : The press had reports on Jan 01, 2005 that Orchid Chemicals Limited is likely to sell one of its molecules. Further, the company might also launch a new molecule. The Exchange, in order to verify the accuracy or otherwise of the information reported in the press and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company. Orchid Chemicals Limited has vide its letter inter-alia stated, "The news item was completely based on market rumours".

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that consequent to the sale of 4,000 shares,Dr.M R Girinath,Director holds 1,92,956 shares of Orchid Chemicals & Pharmaceuticals Ltd. as on December 07,2004

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that International Finance Corporation (IFC) have sold 839850 shares in the secondary market on various dates. Consequently, IFC holds 2188377 shares of Orchid Chemicals & Pharmaceuticals Ltd as of November 24, 2004.

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that the Management Team of Orchid is making a presentation on the Profile & Growth Strategy of Orchid to the press and investors at Hyderabad on November 08, 2004. The same has been uploaded in the Company's website www.orchidpharma.com

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that consequent to the sale of 5,000 shares, Dr. M R Girinath, Director holds 1,97,956 shares of the Company as on September 27, 2004. Further, Mr. Deepak Vaidya, Director's shareholding as on September 30, 2004 has become nil, pursuant to the sale of 3,500 shares held by him.

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that consequent to the sale of 5,000 shares, Dr. M R Girinath, Director holds 2,02,956 shares of the company as on September 23, 2004.

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that the Company is issuing a press release on September 23, 2004, in respect of the Company's US drug discovery joint venture, Bexel Pharmaceuticals, which has been working on a novel anti-diabetic molecule (BLX-1002), has successfully completed limited proof-of-concept Phase 2(a) clinical trials. The patent application filed for this novel molecule (BLX-1002) by Bexel, in the US patent office has been granted. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > La

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that International Finance Corporation (IFC) have sold 6,51,100 shares in the secondary market on various dates. Consequently, IFC holds 30,28,227 shares of Orchid Chemicals & Pharmaceuticals Ltd as of August 30, 2004.